Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: Gary105 who wrote (486)	2/19/2013 8:08:44 AM
From: Dwayne Hines	Respond to of 534

New job opening for Bioject's California offices - fiercebiotech.com

To: Gary105 who wrote (486)	3/21/2013 6:23:32 PM
From: Dwayne Hines	Respond to of 534

Bioject announcement out - Bioject Medical Technologies Inc. (OTC Pink: BJCT) a developer and manufacturer of needle-free injection therapy systems today announced that it has entered into three international distribution agreements two in the Pacific Rim region and one in the Middle East. The agreements call for the sale of the Biojector®2000 gas-powered device the Bioject® ZetaJet™ spring-powered device and accessories through qualified medical device groups located in Australia the Republic of the Philippines and North Africa. The agreements provide for distribution in multiple territories throughout the regions. “We are pleased to have entered into these agreements as it expands the use of our needle-free devices throughout the world” said Mr. Mark Logomasini Bioject’s President and CEO. “In partnership with our distributors we are looking forward to developing relationships with new users of Bioject’s needle-free technology.”

To: Gary105 who wrote (486)	4/5/2013 10:00:36 AM
From: Dwayne Hines	Respond to of 534

clinical trial A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique (TaMoVac II)